Australia’s Medical Cannabis Exports Doubled in 2025, With Germany Taking the Lead

Exports reached 6,780 kilograms in 2025 and Germany took more than half

Australia’s medicinal-cannabis export trade moved into clearer commercial scale in 2025. The latest country-by-country tables from the Office of Drug Control show Australia exported 6,780 kilograms of cannabis in 2025, up from 3,312 kilograms in 2024.

That is not a marginal rise. It is a doubling year on year, and it changes the shape of the market. For several years, the Australian story was mostly about imports, domestic prescribing and the slow build-out of local cultivation and manufacturing. The new data shows that overseas sales are now becoming material for the sector.

Germany was the decisive market. It took 3,668 kilograms of Australian exports in 2025, or just over half of the total. Czechia was the second-largest destination with 1,500 kilograms. Together, those two European markets absorbed about three quarters of Australia’s outbound volume. Other destinations were much smaller, including nearby New Zealand.

The export rise matters because it arrived alongside a large domestic production base. Australia produced 55,337 kilograms of cannabis in 2025 and ended the year holding 50,755 kilograms in stock, according to the same official tables. In plain terms, local output kept running far ahead of the volume exported, and year-end inventories stayed very high. That makes access to overseas buyers more than a side business. It becomes one of the few visible ways to move surplus product through the system.

A useful comparison is export share. Even after doubling, exports were only a little over 12 percent of annual production. That means the story is not that Australia has become an export-led industry overnight. The story is that exports have moved beyond token volume and are now large enough to matter, without yet being large enough to solve the stock problem on their own.

This is why the August 2026 update from the Office of Drug Control matters now. It gives the first clean official picture of where the 2025 market actually went, country by country, and it shows concentration rather than broad diversification. Germany was not simply a leading destination. It was the anchor that made the year’s export total possible.

Every shipment still needs a licence, a permit and the buyer country’s approval

The trade figures look commercial, but the system underneath them is still tightly controlled. Australia does not allow medicinal-cannabis exports to move like ordinary packaged consumer goods. The product sits inside the narcotics control system, which means the regulator checks both the exporter and the shipment.

In practice, that means a company needs an export licence to operate in this part of the market, and it also needs a permit for each individual consignment. A consignment is a specific shipment, not a general right to trade for a year. The application must also include proof that the receiving country has authorised the import. So the Australian permission and the foreign permission have to line up shipment by shipment.

That structure helps explain why large export numbers matter. A total of 6,780 kilograms was not achieved by a single broad commercial approval. It had to be assembled through repeated compliant shipments, each matched to a destination market that was itself willing and able to receive the goods under local law.

The Office of Drug Control’s guidance also makes clear that this is not just about growing cannabis and finding a buyer. Exported medicinal cannabis has to sit inside a chain that includes licensed cultivation or manufacture, product controls, transport security and documentary compliance. For general readers, the practical point is simple. Selling abroad is harder than producing at home. The barrier is not only whether a plant can be grown. It is whether a shipment can meet medicine rules, customs rules and narcotics controls in two countries at once.

Australia already has some of the supply-chain base needed for that. The public list of approved manufacturers and suppliers maintained by the regulator shows that the domestic market has built out beyond cultivation into processing, packaging and supply functions. That does not guarantee export success, but it does show the country is not starting from scratch.

Manufacturing compliance matters here as well. The Therapeutic Goods Administration, Australia’s medicines regulator, tracks good manufacturing practice clearance activity. Good manufacturing practice is the baseline quality system used to show that medicines are made consistently and safely. The regulator’s current dashboard shows the backlog of pending clearance applications fell sharply between the third quarter of 2025 and early September 2026.

That backlog reduction is not the same thing as an export boom, and it should not be confused with an export permit. But it is relevant context. International medicinal-cannabis trade works more smoothly when quality and manufacturing paperwork moves through the system with less delay. Buyers in overseas medical markets are not just purchasing plant material. They are purchasing something that must sit inside a medicines framework.

The regulator’s 2026-27 cost recovery statement adds another useful signal. It shows medicinal cannabis regulation is now handled as an established administrative system with recurring fees, permit processing and licence oversight. This is no longer a small experimental corner of Australian drug policy. It is a standing market with standing bureaucracy.

High production and high stock mean overseas demand now matters to growers and manufacturers

The immediate commercial consequence of the 2025 data is that exports now have to be taken seriously by Australian operators. That applies first to cultivators and manufacturers, because they carry the burden of large output and large inventories.

A production figure of 55,337 kilograms and a year-end stock figure of 50,755 kilograms tell a blunt story. Australia can produce at volume, but much of that volume still sits in the system. Stock can be useful. It can support continuity of supply, batch planning and different product formats over time. But large stock also ties up capital, storage capacity and working plans. Product sitting in inventory is not the same as product sold.

That is where Germany’s role becomes so important. Germany has become Europe’s largest and most visible medicinal-cannabis market by volume. For an Australian producer with excess capacity, Germany offers something the domestic market cannot always provide at the same scale: a large legal medical channel that already buys internationally. The 2025 data suggests Australian suppliers found a workable route into that demand.

Czechia matters for a different reason. Its 1,500 kilograms show that the export story was not limited to one buyer in one jurisdiction. But it also underlines how concentrated the trade still is. If Germany and Czechia together take around three quarters of total volume, then the export platform is meaningful but narrow.

That concentration affects several parts of the industry.

For growers, it raises the value of crop planning around export specifications rather than only domestic demand. The product that moves into an overseas medical channel may need different formats, testing packages, stability work or contractual timing.

For manufacturers, it increases the importance of processing capacity and documentation discipline. Export markets tend to reward firms that can provide consistent batches and complete technical files, not just biomass.

For companies raising money, the numbers offer both support and caution. Support, because there is now official evidence that export sales exist at scale. Caution, because the route to market is concentrated in a small number of destinations and still depends on permit-based trade. A business case built on exports is stronger than it was a year ago, but it is not broad-based yet.

For policy watchers, the numbers complicate the old view of Australia as mainly an importing medical market with uneven domestic conversion. The country now looks more like a hybrid system. It still has domestic prescribing dynamics and imported product in the mix, but it also has enough local production to push seriously into foreign markets.

New Zealand’s appearance among smaller destinations adds another layer. It suggests that Australia’s export footprint is not only a long-haul Europe story. Regional medical markets can play a role, even if they are currently far smaller than Germany. Over time, a spread of medium-sized destinations would matter more than a single dominant buyer, because it would reduce dependence on one market’s pricing, reimbursement or regulatory shifts.

Australia has proved it can export medicinal cannabis at scale, but not yet that demand is broad or durable

The evidence now supports a firmer conclusion than was possible a year ago. Australia is no longer merely capable of exporting medicinal cannabis. It is doing it in volumes large enough to alter how the sector should be read.

That does not mean the hard part is finished. The first unresolved question is whether 2025 was the start of a durable export corridor or a strong year driven by a few contracts and a favourable opening in Germany. Country concentration matters because it can flatter a headline number. If one market slows, changes reimbursement rules, tightens import conditions or simply shifts to another supplier country, the effect on Australian export totals could be immediate.

The second unresolved question is whether exports will keep pace with production and stock. On current evidence, they do not. Doubling exports is substantial, but inventory levels remain large. Unless outbound demand continues to widen, oversupply pressure will remain a defining feature of the domestic operating environment.

The third question is whether Australian firms can convert supply into finished, compliant, repeatable products rather than one-off shipments. In medicinal cannabis, trade volume is not the whole story. The more durable businesses are usually the ones that can meet medicine-quality expectations consistently across markets, not simply clear biomass out of storage.

That is why the administrative detail matters. Shipment permits, foreign import approvals, manufacturing quality systems and a functioning regulatory workload are not side notes to the story. They are the plumbing that turns production into revenue.

The most sober reading of the 2025 data is this: Australia has built more cannabis production than its home market alone comfortably explains, and exports are becoming the release valve. Germany has shown that the valve can open wide. What has not been proved yet is that enough other markets will open with it.

For the industry, that is a more serious milestone than any simple growth headline. The market has moved from asking whether Australia can export medicinal cannabis at all to asking whether it can build a stable export business that is diversified, compliant and repeatable. The answer is no longer theoretical. It is simply unfinished.